Volume 129, Issue 21

Cover Figure: RNA polymerase I, a potential therapeutic target for aggressive AML. See the article by Hein et al.

WASHINGTON, May 25, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia
Zaimoku et al demonstrate that the functional loss of the HLA-B4002 class I allele is a common event in aplastic anemia, suggesting that this allele plays a major role in the immunopathobiology of the disease.

Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome
Hoeing and colleagues advance our understanding of the clinical presentation and treatment for reticular dysgenesis, a unique subtype of severe combined immunodeficiency.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
This preclinical study demonstrates the remarkable therapeutic potential of RNA polymerase I (Pol I) inhibition in acute myeloid leukemia (AML).

Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions
The authors identify ERK5 as a key signaling molecule associated with platelet hyperreactivity in hyperlipidemia.

Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1
This study reveals a key role for the plasmin system in the resolution of acute inflammation whereby plasminogen/plasmin (Plg/Pla) induce macrophage polarization and the anti-inflammatory effects of Plg/Pla are mediated via the protein annexin A1.

Introduction to a series of reviews on clinical platelet disorders
Introduced by José López and Nancy Berliner, this series of review articles provides an21/ up-to-date examination of several clinical platelet disorders that often perplex clinicians because of their difficulty in diagnosis or complexity in therapy.

The articles in this review series, "Clinical Platelet Disorders," include the following:


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.